697 - 708 of 7403 results

Cost effective, turnkey opportunities that create quality brand exposure. Whether it is signage or a Pre/Post conference mailer, these opportunities will meet your needs.


Make your presence known by marketing your product or service with these high value opportunities. Multiple options providing great exposure to clinicians.


Premium branding opportunities providing the highest level of clinician exposure.


0.5 CME CREDIT

Join Dr. Frank Domino as he discusses an evidence-based approach to diagnosing and managing a condition frequently seen in primary care practice: shoulder pain. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on August 26th, 2020 and they are subject to change as new information is published.


0.5 CME CREDIT

Watch distinguished faculty from Northwestern University examine clinical trial data and the latest evidence-based guidelines for hypercholesterolemia to help you develop a practical approach to lipid management for primary care. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on August 12, 2020, and they are subject to change as new information is published.


PrimaryCareNOW: Recorded Live on August 13, 2020

3.00 CME/MOC
3.00 AANP | 2.25 Pharmacology


Join us as we examine the risk of hospitalization for heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF reduction in patients with T2D and established CV disease or multiple CV risk factors. We'll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.


Short-acting B2-agonists (SABA) have been the mainstay of rescue therapy in asthma, regardless of disease severity. However, we must ask ourselves: at what point does SABA use indicate poor asthma control, and can we do more to prevent exacerbations and oral corticosteroid exposure? This program will examine the relationship between SABA reliance, disease control, and patient behavior and review real world evidence updates to highlight a window of opportunity to prevent exacerbations.